BC-11 (hydrobromide)

BC-11 hydrobromide is a selective TMPRSS2 inhibitor (TMPRSS2 is a key host cellular factor for viral entry and SARS-CoV-2 pathogenesis), and a selective urokinase (uPA) inhibitor (IC50=8.2 μM) . BC-11 hydrobromide is cytotoxic to triple-negative MDA-MB231 breast cancer cells. BC-11 hydrobromide is used in research on viral infections and cancer[1][2][3].

Product Specifications

CAS Number

[443776-49-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PAI-1; SARS-CoV; Ser/Thr Protease

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/bc-11-hydrobromide.html

Purity

99.0

Solubility

DMSO : 125 mg/mL (ultrasonic) |H2O : 25 mg/mL (ultrasonic)

Smiles

NC(SCC1=CC=C(B(O)O)C=C1)=N.[H]Br

Molecular Formula

C8H12BBrN2O2S

Molecular Weight

290.98

Precautions

H302, H315, H319, H335

References & Citations

[1]Moumbock AFA, et al. BC-11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS-CoV-2 host cell entry. Arch Pharm (Weinheim) . 2023 Jan;356 (1) :e2200371.|[2]Semina E, et al. Urokinase and urokinase receptor participate in regulation of neuronal migration, axon growth and branching. Eur J Cell Biol. 2016 Sep;95 (9) :295-310.|[3]Longo A, et al. Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells. Molecules. 2015 May 28;20 (6) :9879-89.